Most basal-like breast carcinomas demonstrate the same Rb−/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically

2010 ◽  
Vol 2010 ◽  
pp. 29-30
Author(s):  
J. Wisell
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Breast Carcinomas ◽  
Poorly Differentiated

CDX2 Is a Useful Marker of Intestinal-Type Differentiation: A Tissue Microarray–Based Study of 629 Tumors From Various Sites

2005 ◽  
Vol 129 (9) ◽  
pp. 1100-1105 ◽  
Author(s):  
Lindsey B. De Lott ◽  
Carl Morrison ◽  
Saul Suster ◽  
David E. Cohn ◽  
Wendy L. Frankel
Keyword(s):  
Squamous Cell ◽  
Signet Ring Cell ◽  
Squamous Cell Carcinomas ◽  
Intestinal Type ◽  
High Grade ◽  
Poorly Differentiated Neuroendocrine Carcinoma ◽  
Poorly Differentiated ◽  
Lung Adenocarcinomas ◽  
Colorectal Adenocarcinomas ◽  
Neuroendocrine Carcinomas

Abstract Context.—CDX2, a critical nuclear transcription factor for intestinal development, is expressed in intestinal epithelium and adenocarcinomas. Objectives.—To determine if CDX2 is a useful marker for intestinal-type differentiation and to correlate tumor histology with CDX2 staining in colorectal adenocarcinomas. Design.—Tissue microarrays from 71 colorectal adenocarcinomas, 31 hepatocellular carcinomas, 47 lung adenocarcinomas, 55 squamous cell carcinomas of the lung, 69 neuroendocrine carcinomas of the lung and 43 of the pancreas, 57 pancreatic adenocarcinomas, and 256 endometrial adenocarcinomas were stained with antibody against CDX2. Results.—CDX2 staining was positive in 51 (71.8%) of 71 colorectal cancers, including 38 (74.5%) of 51 well- or moderately differentiated tumors and 13 (65.0%) of 20 high-grade tumors. Of the high-grade tumors, 5 (71.4%) of 7 mucinous, 3 (100%) of 3 signet ring cell, and 5 (50.0%) of 10 poorly differentiated tumors were positive. Other tumors showing occasional CDX2 staining included 1 of 30 well- or moderately differentiated neuroendocrine carcinomas of the lung and 2 of 43 from the pancreas, 1 of 47 lung adenocarcinomas, 3 of 57 pancreatic adenocarcinomas, and 15 of 256 endometrial carcinomas. Hepatocellular, poorly differentiated neuroendocrine carcinoma of the lung and squamous cell carcinomas of the lung were not immunoreactive for CDX2. Conclusions.—CDX2 is a useful marker for intestinal-type differentiation, is rarely seen in tumors from the other sites evaluated, and may be useful in determining the site of origin for some metastatic tumors. However, CDX2 is not a sensitive marker for poorly differentiated colorectal carcinoma.

Head-to-Head Comparison of p63 and p40 in Non-Neuroendocrine Carcinomas of the Tubal Gut

2020 ◽  
Vol 28 (8) ◽  
pp. 835-843
Author(s):  
Ahmed M. Bakhshwin ◽  
Ilyssa O. Gordon ◽  
Kathryn Bock Brown ◽  
Xiuli Liu ◽  
Daniela S. Allende
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Control Group ◽  
Targeted Agents ◽  
Gi Tract ◽  
Positive Score ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Objectives. With targeted agents, characterizing carcinomas of the gastrointestinal (GI) tract has become more important. We aim to determine the usefulness of p40 in classifying GI tract carcinomas. Methods. Seventy-five GI carcinomas including 28 squamous cell carcinomas (SCC), 2 adenosquamous carcinomas (ASCA), 21 poorly differentiated carcinomas (PDCA), and 24 adenocarcinomas (AdCA; control group) were stained for p40, p63, and CK5/6. Tumors were scored from 0 to 5 based on extent of staining and marked as positive (score >2) or negative. Results. p63 was positive in 100% of SCC/ASCA and 12.5% of AdCA. p40 was positive in 92.5% of SCC/ASCA and 4.1% of AdCA. In the PDCA subset, a panel including p63, p40, and MOC31 was the best way to accurately classify most cases. Conclusions. p63 and CK5/6 are more sensitive but less specific than p40 for SCC/ASCA in GI carcinomas. In PDCA, a panel approach including p63, CK5/6, and p40 may be best in classifying these cases.

Bilateral Rostral Maxillectomy and Nasal Planectomy for Large Rostral Maxillofacial Neoplasms in Six Dogs and One Cat

2004 ◽  
Vol 40 (2) ◽  
pp. 137-146 ◽  
Author(s):  
B. Duncan X. Lascelles ◽  
Ralph A. Henderson ◽  
Bernard Seguin ◽  
Julius M. Liptak ◽  
Stephen J. Withrow
Keyword(s):  
Postoperative Complications ◽  
Local Recurrence ◽  
Squamous Cell ◽  
Intraoperative Complications ◽  
Squamous Cell Carcinomas ◽  
Complete Excision ◽  
Poorly Differentiated

This paper describes in detail an aggressive rostral maxillectomy procedure in one cat and six dogs, and the postoperative complications and outcomes are reported. The surgeries were performed to attempt complete excision of large and extensive rostral maxillary fibrosarcomas (n=4), squamous cell carcinomas (n=2), or poorly differentiated mesenchymal neoplasia (n=1). The surgeries involved transection of the maxilla at the level of premolar (PM)1 and PM2 in a cat and two dogs, and between PM2 and PM3 in four dogs. There were no intraoperative complications. Complete margins of resection were obtained in all cases. The postoperative appearance was acceptable to owners. Local recurrence was only observed in one dog (10 months after surgery) during a follow-up period of 11 to 66 months (median, 21.5 months).

Immunohistochemical Expression of Fatty acid Synthase, Ki-67 and p53 in Squamous Cell Carcinomas of the Larynx

2008 ◽  
Vol 23 (3) ◽  
pp. 176-181 ◽  
Author(s):  
M. De Vincentiis ◽  
P. Di Cello ◽  
F. Censi ◽  
M. Leopizzi ◽  
S. Natalizi ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Squamous Cell ◽  
Fatty Acid Synthase ◽  
Prognostic Indicator ◽  
Squamous Cell Carcinomas ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Energy Needs ◽  
Laryngeal Carcinomas ◽  
Poorly Differentiated

Fatty acid synthase (FAS) is a recently discovered molecule involved in the energy supply to normal cells. FAS is overexpressed in neoplastic tissues because of their increased energy needs. We explored the immunohistochemical expression of FAS, Ki-67 and p53 in squamous cell carcinomas (SCC) of the larynx and their association with clinicopathological features and outcome. Specimens from 43 patients with SCC were evaluated. Statistical analysis revealed an association between poorly differentiated laryngeal carcinomas and FAS expression (p<0.005) and between FAS and Ki-67 overexpression (p<0.001). Finally, FAS expression was associated with overall survival (p<0.001). We suggest that FAS is a powerful prognostic indicator whose strength can be enhanced when it is evaluated together with clinicopathological data and Ki-67 expression.

scholarly journals Loss of CRABP-II Characterizes Human Skin Poorly Differentiated Squamous Cell Carcinomas and Favors DMBA/TPA-Induced Carcinogenesis

2016 ◽  
Vol 136 (6) ◽  
pp. 1255-1266 ◽  
Author(s):  
Daniela Passeri ◽  
Elena Doldo ◽  
Chiara Tarquini ◽  
Gaetana Costanza ◽  
Donatella Mazzaglia ◽  
...  
Keyword(s):  
Human Skin ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Poorly Differentiated ◽  
Crabp Ii

scholarly journals A Qualitative Transcriptional Signature for the Histological Reclassification of Lung Squamous Cell carcinomas and Adenocarcinomas

2019 ◽  
Author(s):  
Xin Li ◽  
Gengen Shi ◽  
Qingsong Chu ◽  
Wenbin Jiang ◽  
Yixin Liu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Squamous Cell Carcinomas ◽  
Transcriptional Signature ◽  
Poorly Differentiated ◽  
Histological Reclassification ◽  
Hematoxylin Eosin ◽  
Relative Gene

Abstract Background Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. Results Using gene expression profiles of pathologically-determined lung squamous cell carcinomas and adenocarcinomas, denoted as pSCC and pADC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5>AGR2 in pSCC and KRT5

scholarly journals A Qualitative Transcriptional Signature for the Histological Reclassification of Lung Squamous Cell carcinomas and Adenocarcinomas

2019 ◽  
Author(s):  
Xin Li ◽  
Gengen Shi ◽  
Qingsong Chu ◽  
Wenbin Jiang ◽  
Yixin Liu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell ◽  
Expression Profiles ◽  
Squamous Cell Carcinomas ◽  
Marker Genes ◽  
Specific Marker ◽  
Consensus Clustering ◽  
Transcriptional Signature ◽  
Poorly Differentiated ◽  
Pathological Assessment

Abstract Background: Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. Results: Using gene expression profiles of pathologically-determined lung adenocarcinomas and squamous cell carcinomas, denoted as pADC and pSCC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5 > AGR2 in pSCC and KRT5 < AGR2 in pADC. In the two test datasets with relative unambiguous NSCLC types, the apparent accuracy of the signature were 94.44% and 98.41%, respectively. In the other integrated dataset for frozen tissues, the signature reclassified 4.22% of the 805 pADC patients as SCC and 12% of the 125 pSCC patients as ADC. Similar results were observed in the clinical challenging cases, including FFPE specimens, mixed tumors, small biopsy specimens and poorly differentiated specimens. The survival analyses showed that the pADC patients reclassified as SCC had significantly shorter overall survival than the signature-confirmed pADC patients (log-rank p = 0.0123, HR = 1.89), consisting with the knowledge that SCC patients suffer poor prognoses than ADC patients. The proliferative activity, subtype-specific marker genes and consensus clustering analyses also supported the correctness of our signature. Conclusions: The non-subjective qualitative REOs signature could effectively distinguish ADC from SCC, which would be an auxiliary test for the pathological assessment of the ambiguous cases.

scholarly journals A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas

BMC Genomics ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Xin Li ◽  
Gengen Shi ◽  
Qingsong Chu ◽  
Wenbin Jiang ◽  
Yixin Liu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell ◽  
Expression Profiles ◽  
Squamous Cell Carcinomas ◽  
Marker Genes ◽  
Specific Marker ◽  
Consensus Clustering ◽  
Transcriptional Signature ◽  
Poorly Differentiated ◽  
Pathological Assessment

Abstract Background Targeted therapy for non-small cell lung cancer is histology dependent. However, histological classification by routine pathological assessment with hematoxylin-eosin staining and immunostaining for poorly differentiated tumors, particularly those from small biopsies, is still challenging. Additionally, the effectiveness of immunomarkers is limited by technical inconsistencies of immunostaining and lack of standardization for staining interpretation. Results Using gene expression profiles of pathologically-determined lung adenocarcinomas and squamous cell carcinomas, denoted as pADC and pSCC respectively, we developed a qualitative transcriptional signature, based on the within-sample relative gene expression orderings (REOs) of gene pairs, to distinguish ADC from SCC. The signature consists of two genes, KRT5 and AGR2, which has the stable REO pattern of KRT5 > AGR2 in pSCC and KRT5 < AGR2 in pADC. In the two test datasets with relative unambiguous NSCLC types, the apparent accuracy of the signature were 94.44 and 98.41%, respectively. In the other integrated dataset for frozen tissues, the signature reclassified 4.22% of the 805 pADC patients as SCC and 12% of the 125 pSCC patients as ADC. Similar results were observed in the clinical challenging cases, including FFPE specimens, mixed tumors, small biopsy specimens and poorly differentiated specimens. The survival analyses showed that the pADC patients reclassified as SCC had significantly shorter overall survival than the signature-confirmed pADC patients (log-rank p = 0.0123, HR = 1.89), consisting with the knowledge that SCC patients suffer poor prognoses than ADC patients. The proliferative activity, subtype-specific marker genes and consensus clustering analyses also supported the correctness of our signature. Conclusions The non-subjective qualitative REOs signature could effectively distinguish ADC from SCC, which would be an auxiliary test for the pathological assessment of the ambiguous cases.

Sign in / Sign up

Export Citation Format

Share Document